Mitochondrial-Derived Peptide • Discovered 2015

MOTS-c: The Exercise Mimetic Mitochondrial Peptide

📄 4 PubMed citations

A 16-amino acid peptide encoded in mitochondrial DNA that activates AMPK, regulated metabolic homeostasis in mice, and is raised by exercise in humans.

Last updated: November 2026 · Research status: Investigational, mostly preclinical

🧪 Buy MOTS-c at Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items
16
Amino acids · encoded in the mitochondrial 12S rRNA gene
2015
Year discovered · Dr. Pinchas Cohen lab, USC

Track your vials and inventory on paper

Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →
FDA status · 2026 PCAC vote

On July 23–24, 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend MOTS-c for the 503A compounding list. It is a non-binding recommendation — not FDA approval and not legal to compound yet, pending HHS action and formal rulemaking. Read the full vote breakdown →

How MOTS-c Works

MOTS-c is one of a handful of known mitochondrial-derived peptides (MDPs). Its biology links mitochondrial metabolism to nuclear gene regulation and whole-body metabolism.

🧬
Encoded in Mitochondrial DNA

MOTS-c is translated from an open reading frame within the 12S rRNA gene of mitochondrial DNA. Its discovery paper presents it as a further mtDNA-encoded signaling peptide, after humanin. Unlike nuclear-encoded peptides, it is encoded in the mitochondrion's own genome (Lee 2015).

⚡
AMPK Activation via One-Carbon Metabolism

MOTS-c inhibits the folate cycle and the de novo purine biosynthesis tied to it, which leads to activation of AMPK, the cell's energy sensor and the same switch exercise activates. Its primary target organ appears to be skeletal muscle (Lee C et al., 2015).

🔋
Metabolic Homeostasis

In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity (Lee C et al., 2015). The authors propose that mitochondria regulate metabolic homeostasis partly through peptides like this one.

🏃
Retrograde Mitochondrial Signaling

In humans, exercise raises MOTS-c in skeletal muscle and in circulation (Reynolds JC et al., 2021). This has led researchers to study it as a mitochondrial signal that communicates with the rest of the cell and body.

🧪
Stress Response & Nuclear Translocation

After metabolic stress, MOTS-c moves to the nucleus in an AMPK-dependent way and regulates a broad range of nuclear genes, including genes with antioxidant response elements (ARE). It interacted with ARE-regulating stress-response transcription factors such as NRF2 (Kim KH et al., Cell Metabolism, 2018).

🦠
Insulin Sensitization & Glucose Regulation

In high-fat-fed male mice, MOTS-c reduced weight gain and improved glucose tolerance; a K14Q variant of the peptide did not, and it showed weaker insulin-sensitizing activity in vitro (Zempo H et al., 2021).

Exercise in a Peptide

Exercise raises MOTS-c in humans, and MOTS-c treatment improved physical performance in young, middle-aged, and old mice.

In humans, a single bout of exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation (Reynolds JC et al., Nature Communications, 2021). Whether MOTS-c mediates the benefits of exercise in humans has not been shown. The exact magnitude of induction varies between individuals and studies.

MOTS-c Falls With Age

In a cross-sectional human study (n=85), age was a significant predictor of serum MOTS-c, with levels lower at older ages (Ozkaya DY et al., 2025). It is correlational and reports no age-band levels.

⏳
Why Levels Drop

Why levels are lower at older ages has not been established. Age-related decline in mitochondrial function is one proposed explanation, but none of the studies cited here tests it. What has been shown is that exercise raises MOTS-c in human muscle and blood (Reynolds JC et al., 2021).

🔬
The Metabolic Parallel

Whether lower MOTS-c contributes to metabolic aging is unproven. In the same human study, higher insulin resistance (HOMA-IR) went with higher serum MOTS-c, and levels did not differ between people with and without obesity, so human data do not yet show a simple link.

What the Studies Show

Most MOTS-c data is preclinical (mice and cells). The human data cited here is observational: exercise sampling, a cross-sectional blood-level study, and a population-genetics study.

Study 01: Discovery
The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
Lee C et al. · Cell Metabolism · 2015 · USC/Cohen Lab

The discovery paper. It reported MOTS-c, encoded in the mitochondrial 12S rRNA, as a further mtDNA-encoded signaling peptide after humanin. MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, and promoted metabolic homeostasis. AMPK activation partly mediated its actions in cells, and skeletal muscle appeared to be its primary target organ.

PMID: 25738459
Study 02: Exercise Biology
MOTS-c is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis
Reynolds JC et al. · Nature Communications · 2021

Showed that MOTS-c significantly enhances physical performance in young, middle-aged, and old mice, and regulates nuclear genes tied to metabolism and skeletal-muscle adaptation. Late-life intermittent MOTS-c treatment increased physical capacity and healthspan in mice. In humans, exercise induced endogenous MOTS-c expression in skeletal muscle and circulation.

PMID: 33473109
Study 03: Aging
MOTS-c Levels in Individuals With and Without Obesity and Its Association With Inflammation, Insulin Resistance and Endothelial Dysfunction
Ozkaya DY et al. · Archives of Endocrinology and Metabolism · 2025

Cross-sectional human study (n=85). Multiple regression identified age as a significant predictor of serum MOTS-c, with levels declining as age increased. Notably, MOTS-c showed no difference between obese and normal-weight individuals and a positive correlation with HOMA-IR, so the relationship between circulating MOTS-c and insulin resistance in humans is not yet established. Correlational; does not establish causation.

PMID: 41004666
Study 04: Population Genetics
A Pro-Diabetogenic mtDNA Polymorphism in the Mitochondrial-Derived Peptide, MOTS-c
Zempo H et al. · Aging (Albany NY) · 2021

An Asian-specific mtDNA variant (m.1382A>C) produces a K14Q substitution in MOTS-c. In a meta-analysis of three cohorts (n≈27,500), males (not females) carrying the C-allele had a higher prevalence of type 2 diabetes. In one cohort (J-MICC), the higher prevalence appeared only in male carriers with the lowest physical activity: a gene-by-exercise interaction. In mice, K14Q-MOTS-c failed to improve glucose tolerance, and in vitro the variant showed diminished insulin-sensitizing activity. This ties MOTS-c biology to human metabolic-disease risk; it does not demonstrate a longevity benefit.

PMID: 33468709

Research Dosing Protocols

All dosing information is from preclinical (mouse) research only. MOTS-c is not approved for human use. These figures are for educational reference.

⚠️ Research Compound: Not for Therapeutic Use

MOTS-c is an investigational peptide. No FDA-approved dosing protocol exists. Animal-to-human dose extrapolation is unreliable for peptide hormones. All information below is derived from published research and is presented for educational purposes only.

Animal Research
0.5–15 mg/kg/day
Mouse doses in the studies cited here: 0.5 mg/kg/day by intraperitoneal (IP) injection in high-fat-fed mice (Lee C et al., 2015), and 5 or 15 mg/kg/day IP, daily for 2 weeks or 3x/week in a late-life study (Reynolds JC et al., 2021).
Route of Administration
Injection
The mouse studies cited here gave MOTS-c by intraperitoneal injection. No peer-reviewed human dosing study is cited on this page, and there is no oral bioavailability data in humans.
💉
Reconstitution

MOTS-c is typically supplied lyophilized (freeze-dried powder). No study cited on this page covers reconstitution volumes. Store reconstituted peptide refrigerated and follow the supplier's handling instructions. See our reconstitution guide for full protocol.

🕐
Timing Considerations

No study cited on this page establishes an optimal dosing time. Optimal timing in humans has not been established.

Safety Considerations

Human safety data for injected MOTS-c is limited: no peer-reviewed human dosing or safety study is among the sources cited on this page. These considerations are based on available research.

⚠️
Limited Human Data: The safety and efficacy data cited here come from mice and cells. Extrapolating from short animal studies to human or chronic use is not supported by current evidence.
🩺
Hypoglycemia Risk: Given MOTS-c's insulin-sensitizing mechanism, use alongside insulin, GLP-1 agonists, SGLT2 inhibitors, or sulfonylureas may increase hypoglycemia risk. Diabetics or pre-diabetics considering research use should exercise particular caution and monitor glucose.
🧬
Mitochondrial Signaling Complexity: MOTS-c modulates nuclear gene expression and interacts with core metabolic pathways. Potential off-target effects on proliferative tissues, immune function, or endocrine axes have not been fully characterized in humans.
🚫
Not for Use In: Pregnancy, breastfeeding, active cancer, autoimmune conditions, or severe hepatic/renal impairment. No safety data exists for these populations.
💉
Injection Route Unstudied in Humans: The mouse studies cited here gave MOTS-c by intraperitoneal injection; no human route or injection protocol has been studied. Any injection can cause local redness, swelling, or bruising, and non-sterile technique risks contaminated vials and infection.

Who Is MOTS-c Research For?

No study cited on this page gives MOTS-c to people: the human data here is observational (exercise sampling, a cross-sectional study, a genetics meta-analysis). These are the research areas interest focuses on, and the groups who should avoid it.

✅ Where Research Interest Lies (no human benefit shown yet)
  • Metabolic dysfunction and insulin resistance (treatment data so far is in mice)
  • Exercise-related metabolic signaling (human data so far is observational)
  • Age-related decline in metabolic markers
  • Longevity research on the mitochondrial peptidome
❌ Not Suitable For
  • Pregnant or breastfeeding individuals
  • Children or adolescents (no pediatric data)
  • Active cancer or high cancer risk (proliferative signaling unknown)
  • Those on insulin or hypoglycemic agents without medical supervision
  • Individuals with autoimmune conditions (immune modulation risk)
  • Those expecting FDA-grade safety and efficacy data: it does not exist yet

What We Know vs. What We Don't

What the Research Supports
  • MOTS-c is encoded in mitochondrial DNA and regulated insulin sensitivity and metabolic homeostasis in mice
  • It activates AMPK via one-carbon metabolism disruption
  • Serum levels were lower at older ages in one cross-sectional human study (n=85)
  • Exercise raises circulating MOTS-c in humans
  • Preclinical data shows metabolic and exercise benefits in mice
  • A MOTS-c gene variant (m.1382A>C) is linked to higher type 2 diabetes prevalence in men in Asian cohorts
What We Still Don't Know
  • Optimal human dosing: no established therapeutic protocol
  • Short- and long-term safety of injected MOTS-c in humans
  • Whether preclinical metabolic effects translate to humans at clinical doses
  • Effects on cancer risk, immune function, or longevity in humans
  • Oral bioavailability or alternative non-injection delivery
  • Drug interactions in complex patient populations
  • Whether benefits persist after discontinuation
📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.


Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Educational Purposes Only — Not Medical Advice

This content is for educational and informational purposes only. MOTS-c is an investigational research peptide and is not approved by the FDA or any regulatory body for human therapeutic use. Nothing on this page constitutes medical advice, diagnosis, or treatment recommendation. Do not use MOTS-c or any research peptide based on information found here without consulting a qualified healthcare provider. Peptide research carries unknown risks. Individual responses vary. The information presented reflects the state of published research as of November 2026 and may not reflect subsequent findings.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.